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Abstract
Context: Von Hippel–Lindau (VHL) disease manifests as a variety of benign and
malignant neoplasms. Previous studies of VHL disease have documented several
genotype–phenotype correlations; however, many such correlations are still unknown.
Increased identification of new mutations and patients with previously described
mutations will allow us to better understand how VHL mutations influence disease
phenotypes.
Patients and design: A total of 45 individuals from five unrelated families were
evaluated, of which 21 patients were either diagnosed with VHL disease or showed
strong evidence related to this disease. We compared the patients’ gene sequencing
results with their medical records including CT or MRI scans, eye examinations and
laboratory/pathological examinations. Patients were also interviewed to obtain
information regarding their family history.
Results: We identified four missense mutations: c.239G>T (p.Ser80Ile), linked with VHL
Type 2B, was associated with renal cell carcinoma, pheochromocytoma and hemangioma
in the cerebellum; c.232A>T (p.Asn78Tyr) manifested as RCC alone and likely caused VHL
Type 1; c.500G>A (p.Arg167Gln) mutation was more likely to cause VHL Type 2 than Type
1 as it preferentially induced Pheo and HB in the retina, cerebellum and spinal cord;
c.293A>G (p.Try98Cys) was associated with Pheo and thus likely induced VHL Type 2.
Conclusions: Characterizing VHL disease genotype–phenotype correlations can enhance
the ability to predict the risk of individual patients developing different VHL-related
phenotypes. Ultimately, such insight will improve the diagnostics, surveillance and
treatment of VHL patients.
Precis: Four missense mutations in VHL have been identified in 21 individuals when five
unrelated Chinese families with VHL disease were analyzed; VHL mutations are highly
associated with unique disease phenotypes.
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Introduction
Von Hippel–Lindau (VHL) disease is a rare autosomal
dominant disease that manifests as a variety of benign
and malignant neoplasms, including retinal hemangioma
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(HB), HB of the central nervous system (CNS), pancreatic
neuroendocrine
tumor
(NET)
or
cystadenoma,
pheochromocytoma (Pheo) and clear cell renal cell
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carcinoma (RCC) (1, 2). VHL disease is primarily caused
by inactivation of the VHL tumor-suppressive protein.
A dysfunctional VHL leads to reduced ubiquitylation
and proteasomal degradation of the hypoxia-inducible
factors (HIFs), HIF-1α and HIF-2α. Elevated levels of HIFs
subsequently result in overactivation of the downstream
pathways involved in vascular endothelial growth factor,
platelet-derived growth factor and transforming growth
factor-α (3). Patients with VHL disease exhibit diverse
phenotypes. For example, some patients manifest either
RCC or Pheo, and some with both. VHL disease is generally
classified into two subtypes: Type 1 (without Pheo) and
Type 2 (with Pheo) (4). Type 2 disease can be further
divided into three sub-categories: Types 2A, 2B and 2C.
Patients with Pheo and HB in the CNS, but without RCC
were considered as Type 2A; patients with Pheo, RCC and
other CNS tumors were known as Type 2B, while those
with Pheo alone were categorized as Type 2C.
VHL mutation-induced RCC typically develops
between the ages of 20 and 50 years but rarely in patients
younger than 20 years old (5). This type of RCCs is
often multi-centric and bilateral, arising in conjunction
with both cysts and de novo from the non-cystic renal
parenchyma. In addition, they usually develop at multiple
sites in the kidneys with approximately two-thirds of
such patients showing multiple renal cysts and RCCs (5).
Pancreatic abnormalities are also common in patients
with VHL disease, as about 77% of these patients have
different pancreatic lesions, such as cysts (47%), serous
cystadenomas (11%) and NETs (15%) (5). VHL mutationinduced Pheo usually develops in the adrenal gland or
paraganglia at different ages ranging from <10 years to
>40 years with about 18% of them at a median age of
30 years (6). Pheos are often multiple, bilateral or extraadrenal and are usually asymptomatic. HBs are rare
indolent vascular tumors that may occur sporadically
(75%) or in association with VHL disease (25%).
VHL-associated HBs are frequently multiple and develop
during childhood (<10 years) or in the early teens to
thirties. HB most commonly developed in the cerebellum
(5–30%) and spinal cord (80%) (6).
Variations in disease penetrance have long been
recognized in close relation to genotypes. Previous
studies have documented that specific VHL mutations
are associated with distinct patterns of tumor formation
(7). Since some data suggest that the same mutation
might cause different VHL types in different races (8, 9),
it is critical to fully characterize genotype–phenotype
correlations of this disease in different patient populations.
In this study, we reported five unrelated Chinese families
http://www.endocrineconnections.org
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with VHL disease and analyzed the genotype–phenotype
correlations in this population.

Subjects and methods
Patients
A total of 45 individuals from five unrelated families were
evaluated. Among them, 21 patients were either diagnosed
with VHL disease or showed strong evidence related to
this disease. Based on one of the recent review articles (2),
VHL is the only gene in which mutations are known to
cause VHL disease and these patients have the mutations
resulting in loss-of-function of VHL protein (the genetic
criteria). The clinical criteria for VHL disease include (i)
a positive family history of HB, RCC, Pheo or pancreatic
tumors or cysts and epididymal cystadenoma; (ii) HB in
combination with other tumors including RCC, Pheo,
pancreatic tumors or cysts or epididymal cystadenoma
without a positive family history of VHL disease (2). The
patients’ gene sequencing results were compared with
their medical records including CT or MRI scans, eye
examinations and laboratory/pathological examinations.
Additional information regarding to their family history
was obtained by further interviewing.
Compliance with ethical standards
All procedures involving human participants were
performed in accordance with the ethical standards of
the Institutional Research Committee, the 1964 Helsinki
Declaration and its later amendments or comparable
ethical standards. The Daping Hospital of Third Military
Medical University waived Institutional Review Board
approval for the study. However, written informed
consent for the use of medical records and related images
was obtained from all patients.
Genetic analysis
Total DNA isolated from the peripheral blood of all
five probands was screened for potential mutations
in the following susceptibility genes of Pheos and/or
RCC: SDHAF2 (succinate dehydrogenase complex
assembly factor 2), SDHB (succinate dehydrogenase
subunit B), SDHC (succinate dehydrogenase subunit
C), SDHD (succinate dehydrogenase subunit D), MAX
(MYC-associated factor X), NF1 (neurofibromin 1), RET
(rearranged during transfection), VHL, FH (fumarate
hydratase), FLCN (folliculin), and MET using Target
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International
License.
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Capture-Based Deep Sequencing (BGI Health, Shenzhen,
Guangdong, China). Upon identification of mutations
in the probands, the potential mutations in most of
the respective family members were further screened by
Sanger sequencing.

Results
Cases
Patient 1
A 42-year-old female was admitted to our hospital in May
2015 due to masses in her right kidney and left adrenal
gland. The CT scan showed a mass of 2.5 × 2.1 cm and
multiple cysts in her right kidney (Fig. 1A, upper image),
and a mass of 6.1 × 3.9 cm in her left adrenal gland
(Fig. 1A, middle image), while a MRI of her head showed
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a lesion in her right cerebellum (1.0 × 1.4 cm). In addition,
two large masses (>6 cm) were found in her bilateral
adrenal glands when she was 29 years old, for which she
repeatedly underwent adrenal Pheo resection. At 38 years
of age, she underwent pancreatic mass resection and
pathological analysis of the mass showed a pancreatic NET.
Considering her recurrent and multiple lesions, surgery
was not considered suitable and therefore sunitinib was
prescribed. A few months later, she experienced dizziness,
headache and emesis. In February 2016, she underwent
surgery for the mass in her right cerebellum (Fig. 1A,
bottom image), and HB was confirmed pathologically. In
addition, her eldest brother had RCCs in both kidneys,
HBs in his bilateral cerebellums and Pheo in his left
adrenal gland. Her second brother also had RCC, while her
daughter had Pheos in her bilateral adrenal glands and HB
in her left cerebellum. The patient’s father died from brain

Figure 1 Representative CT and MRI scans from the probands. (A) CT and MRI scans showing lesions in proband 1, including a right renal cell carcinoma
(RCC) (upper image) and left pheochromocytoma (Pheo) (middle image) by CT scan, and a hemangioma (HB) in the right cerebellum (bottom image) by
MRI scan. (B) A CT scan showing RCCs in proband 2. (C) CT scans of Pheos (upper image) and a renal cyst (bottom image) in proband 3. (D) CT and MRI
scans showing the Pheos (upper image) and HB (bottom image) in proband 4. (E) CT scans showing Pheos in proband 5. Red arrows indicate the relevant
features.
http://www.endocrineconnections.org
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tumors. Although without pathological confirmation, he
was most likely suffered HBs based on the family history.
Therefore, we conducted gene sequencing of her DNA
and a pathogenic VHL mutation (c.239G>T; p.Ser80Ile)
(Fig. 2A) was confirmed.

Patient 2
A 50-year-old female was referred to our hospital in
August 2011 for masses in her left kidney (Fig. 1B).
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The CT scan showed several masses in her left kidney and
the largest one was about 3.1 × 2.4 cm. She underwent a
radical nephrectomy 5 years ago for the tumor in her
right kidney. Given the fact that she had already lost
one kidney, sunitinib instead of surgery was prescribed.
Sanger sequencing for potential VHL mutation was
conducted for her and her family members and
c.232A>T (p.Asn78Tyr) mutation was identified in her,
her mother, sister, brother and nephew (Fig. 2B). In fact,
her sister was diagnosed with a pancreatic NET and died
of hemorrhagic stroke at the age of 40 years, and her
mother died of stroke at 50 years of age. Her brother and
nephew refused further examinations for VHL-related
lesions.

Patient 3
The patient was a 24-year-old male who presented with
masses in his bilateral adrenals. In February 2013, he
underwent an abdominal CT scan that revealed masses
in his bilateral adrenals (Fig. 1C, upper image) and a cyst
in his left kidney (Fig. 1C, bottom image). The masses
were subsequently resected by laparoscopic surgery and
pathological analysis confirmed the presence of Pheos.
His mother and aunt died from HBs in their brain, while
his sister and cousin had Pheos in their bilateral adrenals
and right adrenal, respectively. We decide to sequence the
relevant susceptible genes in the proband and confirmed
that he had a heterozygous missense VHL mutation
c.500G>A (p.Arg167Gln) (Fig. 2C).

Figure 2
Gene sequencing data reveal VHL mutations for Families 1 (A), 2 (B), 3 (C),
4 (D), and 5 (E), respectively.
http://www.endocrineconnections.org
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Patient 4
A 21-year-old male reported blurry vision and
metamorphopsia in his left eye for 10 days beginning
on November 9, 2015. An eye examination discovered
a macular hole for which he underwent an operation.
Tissue pathology revealed an HB in his left retina. After
8 months, he was again referred to our hospital for
masses in his bilateral adrenals (Fig. 1D, upper image).
These masses were subsequently resected and the
pathological report confirmed the presence of Pheos.
Additionally, the MRI scan showed a mass in his basal
ganglia region (Fig. 1D, bottom image), a mass in his
left frontal lobe, as well as a mass in his cervical cord,
which were most likely CNS HBs. Sequencing identified
the same heterozygous missense mutation as the family
of patient 3, p.Arg167Gln (Fig. 2D). Additionally, he
revealed that his father also had Pheos in his bilateral
adrenals.
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International
License.
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HB, hemangioma; NET, neuroendocrine tumor; Pheo, pheochromocytoma; RCC, renal cell carcinoma; VHL, Von Hippel-Lindau.
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Table 1 Demographic and disease characteristics of patients with VHL disease.
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Patient 5
The patient was a 10-year-old male who presented with
dizziness and headache for 1 month and blurry vision for
2 weeks. An abdominal CT scan revealed two masses in
his bilateral adrenals (Fig. 1E) and Pheos were confirmed
pathologically. Sequencing screening identified a
heterozygous missense mutation (c.293A>G; p.Try98Cys)
in VHL (Fig. 2E). Additionally, both his grandmother and
mother had Pheos in their bilateral and left adrenals.

Clinical characteristics of patients
In this study, we analyzed a total of 21 patients from five
unrelated families who were either diagnosed with VHL
disease or showed strong evidence support the conclusion
of this disease (Table 1) and their family pedigrees were
shown in Fig. 3. Among all the VHL disease-associated
tumors, Pheo was the most common one (n = 10, 5 men
and 5 women), followed by HB (n = 7, 3 men and 4
women) and RCC (n = 3, 1 men and 2 women). RCC, Pheo
and HB frequently manifested bilaterally or as multiple
lesions. Among this particular cohort, CNS HB is the
leading cause of death due to HB-related hemorrhagic
stroke. Routine eye examinations might be critical for
identifying early manifestations of VHL pathogenesis so
patient care can be managed at earlier points in disease
progression. Two probands were admitted to hospital
because of blurry vision. Wang et al. have described that
HB in CNS and retina represent the most prevalent VHLassociated tumors. By conditional inactivating VHL in a
hemangioblast population using a Scl-Cre-ERT2 transgenic
mouse line, they found that affected VHL-mutant mice
demonstrated retinal vascular lesions associated with
prominent vasculature, anomalous capillary networks,
hemorrhage, exudates and localized fibrosis (10).
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Genotype–phenotype correlations
Four missense mutations were identified in these five
unrelated Chinese families, specifically, c.239G>T
(p.Ser80Ile) in family 1, c.232A>T (p.Asn78Tyr) in family
2, c.500G>A (p.Arg167Gln) in both family 3 and 4 and
c.293A>G (p.Try98Cys) in family 5. All affected members
in Family 1 presented with RCC, Pheo and HB in their
cerebellum, indicating that the mutation (c.239G>T;
p.Ser80Ile) is likely linked to VHL Type 2B. In Family 2, only
RCC developed in the affected individuals, suggesting that
this specific mutation (c.232A>T; p.Asn78Tyr) leads to VHL
Type 1. Pheos and HBs developed more frequently in the
members of families 3 and 4 who bore the same mutation
(c.500G>A; p.Arg167Gln), indicating that this mutation
is likely responsible for VHL Type 2 rather than Type 1.
The proband in family 5 presented with both Pheo and
HB, suggesting that the c.293A>G (p.Try98Cys) mutation
is also linked to VHL Type 2. Although both mutations in
families 3/4 and 5 resulted in Pheos, the tumors carrying
different mutations might have diverse characteristics.
The hormone expression profiles of proband 4 and 5
(Table 2) showed that the Pheo in proband 4 (c.500G>A;
p.Arg167Gln) might be non-functional, while the Pheo in
proband 5 (c.293A>G; p.Try98Cys) could cause hormonal
change and result in the hypertension.

Discussion
In this study, we identified four missense mutations in
five unrelated families with VHL disease and analyzed
the genotype–phenotype correlation in this small
cohort. Based on the genetic mutations and the clinical
diagnoses, we inclined to make the following conclusions:
the mutation c.239G>T; p.Ser80Ile is associated with

Figure 3 Family pedigrees for probands 1 (A), 2
(B), 3 (C), 4 (D), and 5 (E), respectively. ‘I, II, III’
represent generations, ‘□, ○’ indicate normal
males and females, ‘●, ■’ represent male and
female carriers of the corresponding VHL
mutation, dashes between symbols ‘□–○’
indicate a couple and ‘↗’ indicates the probands.
http://www.endocrineconnections.org
https://doi.org/10.1530/EC-18-0167

© 2018 The authors
Published by Bioscientifica Ltd

This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International
License.

Q Liu et al.

876

7:7

Genotype–phenotype
correlations of VHL disease

Table 2 Patients’ hormone expression profiles.
Hormone

Cortisol 8 (ng/mL)
Cortisol 16 (ng/mL)
Cortisol 24 (ng/mL)
ACTH 8 (pg/mL)
ACTH 16 (pg/mL)
ACTH 24 (pg/mL)
Vanillylmandelic acid (μmol/24 h urine)
17-Hydroxycorticosteroid (μmol/24 h urine)
17-Ketosteroid (μmol/24 h)
Orthostatic aldosterone (ng/mL)
Clinostatic aldosterone (ng/mL)
Orthostatic renin activity (ng/mL/h)
Clinostatic renin activity (ng/mL/h)
Orthostatic angiotensin II (pg/mL)
Orthostatic angiotensin II (pg/mL)
Hypertension

Reference range

Proband 4

Proband 5

50–280
20–140
10–120
5.08–32.8
10.7–30.5
5–15
9.6–50.0
5.5–33.2
13.9–76.3
0.1–0.3
0.1–0.2
0.3–5.2
0.1–1.5
19–115
15–97

241
135
81
16.9
24.0
12.5
28.1
16.4
67.2
0.1
0.1
3.4
1.0
79
55
No

312
381
128
—
—
—
116.8
11.3
40
0.1
0.2
17.9
17.1
322
306
Yes

ACTH, adrenocorticotropic hormone.

RCC, Pheo and HB in the cerebellum, while the mutation
c.232A>T; p.Asn78Tyr tended to cause RCC alone; the
mutation c.500G>A; p.Arg167Gln preferentially caused
Pheo and HB in the retina, cerebellum and spinal cord;
the mutation c.293A>G; p.Try98Cys is associated with
Pheo alone.
All four mutations identified in this study have
been reported previously. The mutation c.239G>T;
p.Ser80Ile has been reported to be associated with both
VHL Types 1 (11) and Type 2 (12, 13). However, this
particular mutation in the Chinese family specifically
caused VHL Type 2B. Using molecular modeling of the
VHL–ElonginC–HIF–1alpha complex, the mutation
c.232A>T; p.Asn78Tyr identified in the current study was
previously predicted to be highly associated with RCC,
and therefore, to cause VHL Type 1 (14). We found that
the mutation c.500G>A; p.Arg167Gln in two unrelated
families. This mutation has been first reported by Hes
et al. in three families, of which four patients had RCCs
and three had renal cysts (15) and later by Ciotti et al. in
another two patients (16). In the latter report, one patient
presented with bilateral RCCs while the other suffered
RCCs and both pancreatic and renal cysts. Therefore, this
mutation-associated disease is classified as VHL Type 1 due
to the absence of Pheo. In the current study, this mutation
was associated with both Pheo and HB, and therefore, we
suggest that in Chinese population, this mutation-caused
VHL disease should be classified as Type 2. However, we
are unable to further determine if it is specific for Type 2A
or Type 2B due to the limited size of cohort. The mutation
c.293A>G, p.Try98Cys was previously described in two
Chinese patients, one of them presented with HB and
Pheo, while the other only showed HB. In the current
http://www.endocrineconnections.org
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study, the affected patients in family 5 experienced Pheo
only. Therefore, this mutation should be classified as VHL
Type 2 in the Chinese population.
Patients with VHL disease exhibit diverse phenotypes.
Many factors may underlie this phenotypic diversity,
including the kind or site of the VHL mutation, the
type of amino acid substitutions, modifier genes or
other environmental factors. Of note, different kinds of
mutations can produce remarkably diverse phenotypes.
In VHL patients from non-Chinese population, VHL
deletions or truncations are associated with VHL Type
1, while missense mutations are more likely to cause
VHL Type 2 (7). This is because VHL missense mutations
confer a high risk in development of Pheos (17), while
VHL deletions and truncations confer a higher risk of
CNS HB relative to missense mutations (18). The findings
from a cohort of a large Chinese population also support
the notion that missense mutation confers a high risk of
Pheos development in Chinese VHL patients (19). All four
mutations identified in our study were missenses and only
one of them caused VHL Type 1, while the other three
resulted in VHL Type 2. These findings also support the
notion that missense mutations intend to lead to Pheo.
Mutations at different sites are associated with diverse
risks of VHL-related lesions. For instance, mutations in
the Missense Cluster Regions MCR-1 (residues 74–90)
and MCR-2 (residues 130–136) increase the risk of renal
lesions (20). The mutations p.Tyr98His and p.Tyr112His
confer a low risk for RCC, while p.Tyr98His, p.Ser111Cys,
p.Arg161Gln, p.Leu178Gln and p.Leu188Val confer
a high risk of Pheo (7). It has been reported that
c.241C4T (p.Pro81Ser) missense mutation increases the
risk of RCC and CNS HB (21), while the p.Pro86Leu
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International
License.
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mutation preferentially induces HB (22). Our findings
further substantiated this notion. More importantly,
we found that the same tumor (Pheo) resulted from
different mutations manifest different characteristics.
The mutation c.500G>A; p.Arg167Gln in proband 4
caused non-functional Pheo, while mutation c.293A>G;
p.Try98Cys in proband 5 resulted in hormonal changes
and subsequent hypertension. This finding need to be
further substantiated in a large cohort study.
Different mutations of the same codon can also
produce variable phenotypes. Bradley et al. suggest that
missense mutation c.334T>A (p.Tyr112Asn) caused VHL
Type 1 since most (53.8%) of the affected family members
presented with RCC and only one with Pheo (23). On
the other hand, substitution of histidine for asparagine
(c.334T>C) increases the risk of VHL Type 2A as all the
members in two American families (22 patients) carrying
this mutation had Pheo and none with RCC (24). It has
been speculated that such large phenotypic variation
may resulted from different stabilities of the VHL protein
produced by different amino acid substitutions. By
studying mice carrying VHL-null and Type 2B mutant,
Alexandra et al. demonstrated that diverse phenotypes are
likely resulted from differential effects of specific mutation
on vascular development via downstream perturbations
in Notch signal and in conjunction with other pathway
misregulation (25).
Although most mutations lead to similar genotype–
phenotype correlations across races (26), the same
mutation in patients of different races may also manifest
diverse phenotypes. Crossey et al. showed that the
mutations p.Arg113Ter, p.Gln132Ter, p.Leu158Val and
p.Cys162Tyr are associated with VHL Type 1 in western
cultures (8), whereas a later report by Yoshida et al.
suggested that these mutations are associated with VHL
Type 2 in Japanese (10). Similarly, previous studies showed
that the mutation c.500G>A (p.Arg167Gln) is associated
with RCC and renal cysts in western populations,
suggesting that this mutation causes VHL Type 1 (15, 16,
27), while we found that this mutation in Families 3 and
4 frequently caused Pheo, indicating that this mutation
(c.500G>A; p.Arg167Gln) is likely linked to VHL Type 2 in
the Chinese population.
Different family members bearing the same mutation
could also show distinct phenotypes. It has been reported
that members in the same family with a c.203C>G
(Ser68Trp) mutation demonstrated variable penetrance
of isolated Pheos (28). The proband did not manifest
Pheo until he was age 63 years. By contrast, one of the
proband’s six children presented with an isolated Pheo at
http://www.endocrineconnections.org
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age 23 years, and the proband’s sister developed a Pheo at
the age of 24 years. In addition, two of her three children
are carriers of the mutation and one of them was still
asymptomatic at the age of 35, whilst the other had a Pheo
when she was 12 years old. Taken together, these data
indicate that many other factors, possibly environment,
may affect the phenotypes induced by specific mutations.
Therefore, it is necessary to characterize genotypephenotype correlation between different populations. In
conclusion, better understanding genotype–phenotype
correlation can not only advance our prediction of VHL
disease-associated risks but also improve the diagnosis,
surveillance and treatment of VHL.
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